Protalix BioTherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Protalix BioTherapeutics generated cash of -$1,318,000, which is more than the previous year. Cash used in financing activities reached the amount of $24,666,000 last year. Net change in cash is therefore $6,523,000.
Cash Flow
| 2014 | -29.28M | -1.00M | 46K |
|---|---|---|---|
| 2015 | -24.28M | 39.38M | 6.63M |
| 2016 | -32.09M | -967K | 19.69M |
| 2017 | -9.99M | -1.11M | -1.41M |
| 2018 | -7.74M | -591K | -4.75M |
| 2019 | -19.35M | -883K | 0 |
| 2020 | -26.10M | -19.95M | 46.46M |
| 2021 | -10.28M | 18.92M | 12.07M |
| 2022 | -25M | -5.03M | 8.23M |
| 2023 | -1.31M | -16.71M | 24.66M |
PLX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 17.11M | 38.98M | 18.26M | 17.79M | 37.80M | 51.16M | 63.28M | 76.37M | 54.76M | 86.39M |
Operating activities | ||||||||||
Net income | 8.31M | -14.92M | -27.58M | -6.52M | -18.27M | -26.45M | -85.27M | -29.17M | -27.28M | -29.94M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.19M | 1.08M | 1.11M | 1.30M | 1.61M | 1.67M | 1.92M | 1.98M | 2.37M | 3.14M |
Stock-based compensation expense | 3.44M | 2.08M | 2.37M | 3.12M | 835K | 0 | 337K | 988K | 1.80M | 1.24M |
| Deferred income tax benefit | 3.44M | 2.08M | 2.37M | 3.12M | 835K | 0 | 337K | 988K | 1.80M | 1.24M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -428K | -1.19M | -1.03M | 2.09M | 188K | -3.09M | 25K | -1.13M | 523K | -799K |
Inventories | -2.24M | 1.15M | -4.87M | -4.92M | 414K | -736K | -2.58M | 522K | -2.31M | 1.29M |
Accounts payable | 5.29M | -4.80M | 2.57M | 1.91M | 2.14M | -520K | 4.90M | 2.13M | -1.87M | 954K |
Cash generated by operating activities | -1.31M | -25M | -10.28M | -26.10M | -19.35M | -7.74M | -9.99M | -32.09M | -24.28M | -29.28M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -16M | -37.83M | -20M | 0 | 0 | 0 | 0 | 0 | -90K |
Investments In Property Plant And Equipment | -1.14M | -628K | -1.45M | -655K | -627K | -686K | -971K | -849K | -464K | -785K |
Acquisitions Net | 0 | 0 | 53K | 0 | 0 | 0 | 3K | 20K | 3K | 0 |
Cash generated by investing activities | -16.71M | -5.03M | 18.92M | -19.95M | -883K | -591K | -1.11M | -967K | 39.38M | -1.00M |
Financing activities | ||||||||||
Common Stock Issued | 23.95M | 8.23M | 46.2M | 46.21M | 0 | 0 | 0 | 14K | 6.10M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -34.12M | -215K | 0 | -4.75M | -1.41M | -19.68M | 0 | 0 |
Cash used in financing activities | 24.66M | 8.23M | 12.07M | 46.46M | 0 | -4.75M | -1.41M | 19.69M | 6.63M | 46K |
Net Change In Cash | 6.52M | -21.87M | 20.72M | 473K | -20.01M | -13.35M | -12.11M | -13.09M | 21.60M | -31.63M |
Cash at end of period | 23.63M | 17.11M | 38.98M | 18.26M | 17.79M | 37.80M | 51.16M | 63.28M | 76.37M | 54.76M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |